- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01909245
Islet Cell Transplant for Type 1 Diabetes (TCD)
Islet Transplantation Using a T-Cell Depleting Immunosuppression Induction Regimen
City of Hope National Medical Center, located in Duarte, CA, is hosting a clinical study on islet cell transplantation, an experimental procedure being evaluated as a treatment for patients with type 1 diabetes. Islet cell transplantation involves taking insulin-producing cells from organ donors and transplanting them into the liver of a patient with diabetes. Once transplanted, the islets produce insulin, which can improve blood sugar control and eliminate the need to inject insulin or use an insulin pump.
Anti-thymocyte globulin (ATG) and alemtuzumab (Campath) are anti-rejection medications that work by decreasing a patient's T-cells. T-cells are special white blood cells that recognize and destroy unwanted things like infections but can also attack transplanted cells and organs. Reducing the number of T-cells at the time of transplant may protect islets and improve long-term transplant success. In previous research studies, islet transplantation has been successful in reducing low blood sugar episodes, improving overall blood sugar control, and in some cases, allowing patients with type 1 diabetes to stop taking insulin.
The purpose of this study is to determine if islet cell transplantation using ATG or alemtuzumab, along with additional medications to prevent the body from rejecting the transplanted cells, is a safe and effective treatment for type 1 diabetes. Study participants may receive up to three islet transplants and will be followed for five years to monitor blood sugar control, islet transplant function, and changes in quality of life.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
California
-
Duarte, California, United States, 91010
- City of Hope Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Three different categories of patients with Type 1 Diabetes will be considered for study participation:
- Naïve islet transplant alone (nITA) candidates: T1D patients complicated by frequent/severe hypoglycemia, hypoglycemia unawareness, AND/OR otherwise unstable blood glucose control who have not received a previous transplant (except for a failed pancreas more than 6 months prior to screening)
- Repeat transplant (RT) candidates: T1D patients who have received two or fewer previous islet transplants > 1 month prior to screening, but continue to require exogenous insulin treatment or have an HbA1c > 6.5%
- Islet after kidney transplant (IAK) candidates: T1D patients with a history of successful renal transplant > 3 months prior to screening
Inclusion criteria for all candidates:
- Age 18-68 years
- Type 1 diabetes mellitus for at least 5 years
Ability and willingness to comply with post-transplant regimen, including taking anti-rejection medications, use of reliable contraception, frequent clinic visits, lab tests, careful recording of blood glucose values, insulin doses and medications, and completing detailed follow-up studies
Additional Inclusion Criteria nITA Candidates Only
Unstable blood sugar control characterized by:
Frequent hypoglycemia (blood glucose ≤ 54 mg/dl more than once per week) -AND/OR- Hypoglycemia unawareness (Clarke score of 4 or more) -AND/OR- One or more severe hypoglycemic episodes in 12 months preceding enrollment. -AND/OR- Erratic blood glucose levels that interfere with daily activities -AND/OR- One or more hospital visits for diabetic ketoacidosis in the 12 months preceding enrollment
Additional Inclusion Criteria for RT Candidates Only
One or two or previous islet transplants > 1 month prior to screening with continuing insulin requirements and/or HbA1c > 6.5%
Additional Inclusion Criteria for IAK Candidates Only
- Successful kidney transplant > 3 months prior to screening
- Stable maintenance immunosuppression consisting of tacrolimus alone or in conjunction with sirolimus, mycophenolate mofetil, myfortic or azathoprine; or cyclosporine in conjunction with sirolimus, mycophenolate mofetil, or myfortic +/- ≤ 10 mg/day corticosteroids
- No history of acute rejection related to kidney graft in last 12 months and low risk of rejection
- Under continuing care of physician for kidney graft, who has provided letter in support of candidate's consideration for study participation
Exclusion Criteria:
- Body Mass Index (BMI) > 33
- Insulin requirements > 1.2 units/kg/day
- Known sensitization to both rATG -and- alemtuzumab
- Significant kidney dysfunction
- Significant liver/gall bladder disease
- Significant cardiovascular disease
- Active proliferative retinopathy
- High blood pressure despite appropriate treatment
- High cholesterol/triglycerides despite appropriate treatment
- Anemia or other blood disorders that require medical treatment
- WBC <3,000/ul
- Increased risk of bleeding, other chronic hemostasis disorders, or treatment with chronic anticoagulant therapy
- Recent unresolved acute infection (except for mild skin infection or nail fungal infection), or chronic infection
- Epstein-Barr Virus (EBV) IgG negative
- Any history of malignancy, except for completely resected squamous or basal cell carcinoma of the skin or in situ cancer of the cervix
- Recent history of non-adherence to medical treatment, or inability to demonstrate capacity to comply with strict blood glycemic control and insulin therapy
- Psychiatric illness that is untreated, or likely to interfere significantly with study compliance despite treatment
- Previous organ/tissue transplant, except as noted above
- Administration of live attenuated vaccines within 2 months of enrollment
- Presence of a chronic disease that must be chronically treated with a contraindicated agent
- Use of investigational agents within four weeks of enrollment
- Active alcohol or substance abuse, including cigarette smoking
- Pregnant women, women intending future pregnancy, women of reproductive potential who are unable or unwilling to follow effective contraceptive measures prior to study entry and for as long as they are on immunosuppression medication, and women presently breast feeding are excluded
- Individuals without health insurance
- History of gastric bypass
- Any medical condition that in the opinion of the investigator will interfere with safe participation in the trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm Study
Allogenic Human Islet Cell Transplant with immunosuppression
|
Intraportal (into the liver) infusion of islet cells, with a maximum of three islet transplants.
Other Names:
Anti-rejection medications (to prevent the body from rejecting the islet cells) and other medications to guard against infection and support participant health and/or the health of the transplanted islets.
Gastrin-17 (or GAST-17) - a gut hormone injected under the skin for 30 days (optional treatment for islet dysfunction).
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 1 year post-transplant
Time Frame: 1 year post-transplant
|
1 year post-transplant
|
Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 2 years post-transplant
Time Frame: 2 years post-transplant
|
2 years post-transplant
|
Proportion of subjects who are insulin independent, hypoglycemia free, AND with hemoglobin A1c < or = 6.5% at 5 years post-transplant
Time Frame: 5 years post-transplant
|
5 years post-transplant
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects who are free of severe hypoglycemic episodes AND have a hemoglobin A1c < or = 7.0%
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Other Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Proportion of subjects experiencing reduction/elimination of hypoglycemic episodes
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Duration of insulin independence
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Proportion of subjects who maintain a positive c-peptide secretion response to glucose/glucagon stimulation
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Change in average daily insulin use compared to baseline
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Decline in insulin intake/100,000 IEQ infused
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Insulin secretion during Intravenous Glucose Tolerance Test (IVGTT), IVGTT+arginine stimulation (IVGTT+AST), Maximum Stimulated Insulin Secretion test (MSIS), and/or Mixed Meal Tolerance Test (MMTT)
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Rate of alloimmune rejection
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Rate of autoimmune reactivation
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Incidence and severity of adverse events related to islet transplant procedure
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Incidence and severity of adverse events related to immunosuppression
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Incidence of change in immunosuppression drug regimen
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Incidence of immune sensitization defined by presence of anti-HLA antibodies post-transplant that were absent pre-transplant
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Incidence of discontinuation of immunosuppression
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Improvement in glucose time within range during continuous glucose monitoring
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Improvement in Personal Glycemic State (PGS) score calculated from continuous glucose monitoring
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Incidence of Gastrin-17 use for treatment of islet graft dysfunction AND incidence of change or early discontinuation of Gastrin-17 treatment
Time Frame: +75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
+75 days, +6 months, +12 months, and +2, +3, +4 and +5 years post islet transplant
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Fouad Kandeel, MD, PhD, City of Hope Medical Center
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Glucose Metabolism Disorders
- Metabolic Diseases
- Immune System Diseases
- Autoimmune Diseases
- Endocrine System Diseases
- Diabetes Mellitus
- Diabetes Mellitus, Type 1
- Physiological Effects of Drugs
- Immunologic Factors
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Immunosuppressive Agents
- Gastrins
Other Study ID Numbers
- 12446
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Type 1 Diabetes Mellitus
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
University of California, San FranciscoJuvenile Diabetes Research FoundationCompletedType 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMUnited States, Australia
-
University of Colorado, DenverMassachusetts General Hospital; Beta Bionics, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Diabetes type1 | Type 1 Diabetes Mellitus | Autoimmune Diabetes | Diabetes Mellitus, Insulin-Dependent | Juvenile-Onset Diabetes | Diabetes, Autoimmune | Insulin-Dependent Diabetes Mellitus 1 | Diabetes Mellitus, Insulin-Dependent, 1 | Diabetes Mellitus, Brittle | Diabetes Mellitus, Juvenile-Onset and other conditionsUnited States
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheRoche DiagnosticsCompletedDiabetes Mellitus Type 2, Diabetes Mellitus Type 1Germany
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
Instytut Diabetologii Sp. z o.o.National Center for Research and Development, Poland; Nalecz Institute of Biocybernetics...UnknownType 1 Diabetes Mellitus With Hyperglycemia | Type 1 Diabetes Mellitus With HypoglycaemiaPoland
Clinical Trials on Allogenic Human Islet Cells
-
University of ChicagoRecruiting
-
University of ChicagoActive, not recruiting
-
University of ChicagoRecruitingDiabetes Mellitus, Type 1United States
-
Kenneth Brayman, MDRecruiting
-
City of Hope Medical CenterUniversity of California, Los AngelesRecruitingDiabetes Mellitus, Type 1United States
-
Anterogen Co., Ltd.CompletedCrohnKorea, Republic of
-
Charles CoxCBR Systems, Inc.Not yet recruitingPost-Acute COVID-19 SyndromeUnited States
-
NovocellCHRISTUS Health; Diabetes & Glandular Disease Research Associates, P.A., San...TerminatedDiabetes Mellitus, Type 1United States
-
BioCardia, Inc.Enrolling by invitationHeart Failure, SystolicUnited States
-
National Institute of Allergy and Infectious Diseases...Terminated